From the *Translational Pediatrics and Infectious Diseases Section, Pediatrics Department, Hospital Clinico Universitario de Santiago de Compostela, Santiago de Compostela, Spain; †Genetics Vaccines Infections and Pediatrics Research Group (GENVIP), Healthcare Research Institute of Santiago de Compostela, Santiago de Compostela, Spain; and ‡Members of MENDICOS Research Network are listed in Appendix.
Accepted for publication November 23, 2015.
I.R.-C., L.V.-T. and F.M.-T. contributed equally to this article.
This study was funded by Novartis through an unrestricted grant for research in meningococcal disease granted to Healthcare Research Institute of Santiago (E0409/13). The sponsor of the study agreed the study design but had no role in the data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication. FMT’s research activities have been supported by grants from Instituto Carlos III (Intensificación de la actividad investigadora) and Fondo de Investigación Sanitaria (FIS; PI10/00540 and PI13/02382) del Plan Nacional de I+D+I and “fondos FEDER.” FMT has received research grants and/or honoraria as a consultant/advisor and/or speaker and for conducting vaccine trials from GlaxoSmithKline, Sanofi Pasteur MSD, Merck, Sanofi Pasteur, Pfizer Inc/Wyeth, Novartis, and MedImmune Inc. The rest of the authors have no conflicts of interest or funding to disclose.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s website (www.pidj.com).
Address for correspondence: Federico Martinón-Torres, PhD, Translational Pediatrics and Infectious Diseases Section, Pediatrics Department, Hospital Clínico Universitario de Santiago de Compostela. Travesía da Choupana, s/n, 15706., Santiago de Compostela, Spain. E-mail: [email protected].
